The unique platform design makes it possible to add new treatment arms at any given time. This allows for a rapid and cost-effective screening of new potential treatments and speeds up the process of finding a cure for ALS.
The MAGNET trial is the first international platform trial to focus on finding effective treatments for ALS.
MAGNET stands for Multi-arm, Adaptive, Group-sequential trial NETwork. Currently 16 academic medical centers from 6 countries are involved the MAGNET Trial: the Netherlands, Belgium, the United Kingdom, Ireland, Sweden and Australia.
Benefits of the MAGNET platform trial
Testing multiple treatments at the same time
This increases our chances of finding suitable drugs to treat ALS. The platform trial is adaptive, meaning that treatments can be added and removed from the platform as required.
Minimizing time on placebo
The MAGNET trial-design enables the different treatment arms to share information from the placebo-treated group. This means that patients have a bigger chance of receiving the experimental medicine instead of the placebo drug.
Increasing speed while reducing cost.
Through the adaptive nature of the study, new treatments can be added when they become available. This saves considerable time compared to starting up an entirely new clinical trial for every candidate drug.
MAGNET Treatment arms
The MAGNET adaptive platform trial enables the investigation of multiple treatments at the same time. In addition, new candidate drugs can be added to the platform trial while ineffective ones can be dropped. By doing so, the time that patients are exposed to an ineffective treatment is minimized. The first two drugs that we will investigate are already used to treat other diseases and are safe for ALS patients: these are Triumeq and Lithium carbonate.
Find out more about the MAGNET treatment arms here